Some studies have shown that angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers are better first-line therapy for patients with MetS, especially when type-2 diabetes is present. The gene discussed is ACE; the disease is type 2 diabetes mellitus.